Gilead Sciences | GILD - Los Gastos Financieros De La Deuda

Precio De Mercado
140.47
Cambio Diario
-1.05 -0.74%
Mensual
-4.20%
Anual
33.46%
Q2 Expectativa
135.50




Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 740M 40M 2025-06
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
ALKERMES USD 12.28M 7.63M 2025-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 582K 10K 2025-12
J&J USD 18M 290M 2025-09
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 252M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
United Therapeutics USD 3.1M 100K 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12